| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| 250g |
|
||
| Other Sizes |
| Targets |
1-Methyl-1H-pyrazol-3-amine has been shown to inhibit telomerase activity and can be used as a potential anticancer agent. Telomerase is an enzyme that maintains telomere length in cells, and its activity is upregulated in many cancer cells, allowing them to achieve replicative immortality. Inhibition of telomerase is being investigated as a strategy for cancer therapy. The compound also serves as a crucial intermediate in drug synthesis and plays a role in developing new drugs, as well as in studying enzyme inhibitors and receptor modulators. Its pyrazole ring provides a scaffold for the synthesis of diverse biologically active molecules that may target various enzymes and receptors.
|
|---|---|
| ln Vitro |
1-Methyl-1H-pyrazol-3-amine is an organic substance.
In vitro, 1-methyl-1H-pyrazol-3-amine is used in the synthesis of various compounds, such as drugs, dyes, and polymers. It serves as a crucial intermediate in drug synthesis. The compound has been shown to inhibit telomerase activity and can be used as a potential anticancer agent. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. In medicinal chemistry, it serves as a building block for constructing biologically active molecules. Its amino group allows for acylation, alkylation, and other transformations, enabling the synthesis of diverse derivatives. |
| ln Vivo |
In vivo, 1-methyl-1H-pyrazol-3-amine has shown great pharmacokinetic properties that can be optimized for pharmaceutical research. The compound's telomerase inhibitory activity suggests potential for in vivo evaluation in animal models of cancer. However, specific in vivo studies on the compound are limited. The compound was designed for use in pharmaceutical research, and its derivatives may be evaluated in animal models for therapeutic efficacy.
|
| Enzyme Assay |
Cell-free assays for 1-methyl-1H-pyrazol-3-amine involve studying its telomerase inhibitory activity. The compound is incubated with telomerase enzyme and a telomere substrate, and telomerase activity is measured using standard assays such as the TRAP assay. The compound's ability to inhibit telomerase is assessed by comparing activity in the presence and absence of the compound. Its use as a synthetic intermediate involves standard organic synthesis procedures.
|
| Cell Assay |
Cellular assays for 1-methyl-1H-pyrazol-3-amine involve treating cancer cell lines with the compound and measuring telomerase activity, cell viability, proliferation, and apoptosis. Cells are treated with the compound at various concentrations, and telomerase activity is measured using the TRAP assay. Cell viability is measured using MTT or similar assays. The compound's effects on telomere length and cell senescence may also be assessed. Its derivatives may be evaluated in cell-based systems for various biological activities.
|
| Animal Protocol |
Animal studies for 1-methyl-1H-pyrazol-3-amine are limited. The compound's telomerase inhibitory activity suggests potential for in vivo evaluation in animal models of cancer. The compound has shown great pharmacokinetic properties that can be optimized for pharmaceutical research, suggesting that it may have favorable in vivo properties. However, specific in vivo studies on the compound are not extensively documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 1-methyl-1H-pyrazol-3-amine indicate that it has great pharmacokinetic properties that can be optimized for pharmaceutical research. As a small polar molecule with a molecular weight of 97.12 g/mol, it is expected to have high bioavailability if administered. However, comprehensive pharmacokinetic studies have not been performed. The compound was designed for use in pharmaceutical research, and its pharmacokinetic properties may be optimized through structural modifications.
|
| Toxicity/Toxicokinetics |
Toxicological data for 1-methyl-1H-pyrazol-3-amine are limited. Standard safety precautions for handling pyrazoles and amines apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| Additional Infomation |
1-Methyl-1H-pyrazol-3-amine is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is used in the synthesis of various compounds, such as drugs, dyes, and polymers. It serves as a crucial intermediate in drug synthesis and plays a role in developing new drugs, as well as in studying enzyme inhibitors and receptor modulators. The compound has been shown to inhibit telomerase activity and can be used as a potential anticancer agent. It was designed for use in pharmaceutical research and has shown great pharmacokinetic properties that can be optimized for pharmaceutical research. It is supplied with a purity of ≥99.50% and should be stored in a cool, dry place.
|
| Molecular Formula |
C4H7N3
|
|---|---|
| Molecular Weight |
97.12
|
| Exact Mass |
97.063
|
| CAS # |
1904-31-0
|
| PubChem CID |
137254
|
| Appearance |
Colorless to light green liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
231.4±13.0 °C at 760 mmHg
|
| Flash Point |
93.8±19.8 °C
|
| Vapour Pressure |
0.1±0.5 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
-0.44
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
64
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C[N](N=C1N)C
|
| InChi Key |
MOGQNVSKBCVIPW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H7N3/c1-7-3-2-4(5)6-7/h2-3H,1H3,(H2,5,6)
|
| Chemical Name |
1-methylpyrazol-3-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.2965 mL | 51.4827 mL | 102.9654 mL | |
| 5 mM | 2.0593 mL | 10.2965 mL | 20.5931 mL | |
| 10 mM | 1.0297 mL | 5.1483 mL | 10.2965 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
